A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice
This study aims to generate real-world evidence on the clinical effectiveness and economic burden of ofatumumab (OMB) versus ocrelizumab (OCR) in patients diagnosed with multiple sclerosis (MS) in the United States (US). Clinical effectiveness will be assessed using annualized relapse rate (ARR), while economic burden will be assessed using healthcare resource utilization (HCRU) and healthcare costs (HCC). This study will use two primary data sources that capture longitudinal, de-identified healthcare utilization derived from claims submitted for reimbursement.
📬 Get email alerts for new Paid Research Studies
Free — we'll email you when new matching opportunities appear. No spam, unsubscribe anytime.
New here? Here's how Reward Opportunity works:
🧪 More Paid Research Studies
Universities, hospitals, and companies pay participants for clinical trials and academic studies.
Browse all paid research studies →Not just this one — find everything you qualify for
Our AI scans 8,000+ bounties, settlements, grants, recalls, and paid studies against your profile to rank what you can actually claim.
Get My Free Match Report